Huang LC, Topping KL, Gratzinger D, Brown RA, Martin BA, Silva RA, Kossler AL. Orbital and chorioretinal manifestations of Erdheim-Chester disease treated with vemurafenib.
Am J Ophthalmol Case Rep 2018;
11:158-163. [PMID:
30094395 PMCID:
PMC6076364 DOI:
10.1016/j.ajoc.2018.07.005]
[Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2018] [Revised: 07/17/2018] [Accepted: 07/23/2018] [Indexed: 12/12/2022] Open
Abstract
Purpose
We report a patient with severe multi-organ dysfunction of unknown origin who presented with bilateral orbital and chorioretinal manifestations that led to the diagnosis of Erdheim-Chester Disease (ECD).
Observations
ECD is a rare, histiocytic, proliferative disorder characterized by multi-systemic organ involvement that has historically lacked effective therapy. Our patient underwent genetic testing that was positive for the BRAF V600E mutation; therefore, the patient was treated with vemurafenib.
Conclusions and importance
This case demonstrates the rare orbital and intraocular manifestations of ECD and the unfortunate impact of a delayed diagnosis, the importance of early gene therapy testing for management decisions, and the utilization of targeted directed therapy to improve visual outcomes and quality of life.
Collapse